On July 17, 2013, the United States International Trade Commission (ITC) Administrative Law Judge granted the termination of a 337 investigation of Apex’s breathing treatment system and mask products.
This investigation originated from a filing by ResMed requesting the ITC to investigate whether certain of Apex’s product models for breathing treatment systems and masks infringed ResMed’s patents. The ITC instituted the investigation at the close of this April.
In the order granting Apex’s motion to terminate the investigation, the Administrative Law Judge rejected ResMed’s oppositions and confirmed that Apex’s stipulations completely comply with all Commission rules. The stipulations include that Apex does not admit that its products infringe upon ResMed’s asserted patents.
Apex’s lawful operation in the United States is completely undisturbed. Apex remains focusing on product development and innovation while actively expanding its market worldwide.

About Apex
Apex markets a global brand for breathing treatment systems and possesses exceptional ability in product development, manufacture, and marketing. Operating under principles of integrity, professionalism, and innovation, our excellent team of professionals specializing in medicine, engineering, materials, organization, and clinical trials has been devoted to developing its own technology and intellectual property. We aim to provide consumers worldwide top-quality products and to become the leading company in the market for breathing treatment products.

Global - English
Mattress Feature
Risk of Developing a Pressure Ulcer


We use cookies to optimize this website and continuously update it according to your needs.Please click on "Cookies" for detailed information on the use of cookies on this website. If you click "Yes, I agree", cookies will be activated. If you do not want cookies to be activated, you can opt out here. The settings can be changed at any time under "Cookies".

Yes, I agree.